Good afternoon everyone and thank you for joining us today to review Hemispherx 2017 Fiscal Year-End Conference Call. Representing the company today is Mr. Thomas Equels, Chief Executive Officer. We are obliged by law to provide certain legal and binding disclaimers before we begin. Words such as intends, plans, potential, beliefs, potentially, possible and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Hemispherx that of its plans will be achieved. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond Hemispherx’s control, which could cause actual results to differ materially from these contemplated in these forward-looking statements. For example, because numerous risks and uncertainties exists despite our efforts and belief regarding approvals, we cannot assure Ampligen will ever be commercially approved for any treatment, or that Alferon N Injection will ever be commercially approved for potential new treatment indications, or for the new manufacturing procedures underway. Examples of such risks and uncertainties include the risks described in Hemispherx’s filings with the Securities and Exchange Commission, including the most recent reports on Forms 10-K, 10-Q, and 8-K. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof, and Hemispherx undertakes no obligations to update or revise the information discussed on this conference call, whether as a result of new information, future events or circumstances or otherwise revised or update this information to reflect events or circumstances after the date hereof. With that covered, it is now my pleasure to turn the floor over to your host, Mr. Thomas Equels, President and Chief Executive Officer of Hemispherx Biopharma. Sir, the floor is yours.

Good afternoon, everyone. I’m Tom Equels. Welcome to Hemispherx’s second quarter conference call. Today, I’ll start by summarizing Hemispherx's accomplishments since our last conference call which reviewed our corporate and business highlights. And finally, I will give a financial overview for the six months ended June 30, 2017. I have incorporated the topics of the questions that we have received into my discussions. We've had some very important events occur at our company during the past year and since our last call, events that I am very enthusiastic about. The most overarching of which is our decision to repurpose Ampligen beyond the single indication of ME/CFS so as to maximize the potential of this proven immunotherapeutic in indications in which a healthier and more stimulated immune system can play an important role in successful medical outcomes. This decision was based on reams of scientific data in human trials in oncology which frankly got buried in the company's files some years ago in favor of a once total focus on ME/CFS. That we'll describe later, we have taken Ampligen now into pancreatic cancer and we're looking closely at opportunities for Ampligen as a vaccine adjuvant. We're very excited to have been able to announce a few days ago that the study with the Ampligen plus FluMist a human safety trial known as AMP-600 has been completed. We know now that like in the intravenous application to Ampligen where Ampligen was almost 100,000 doses having been administered is generally well tolerated in human fit, inter-nasally we have every indication that Ampligen is generally well tolerated in human, this is very important. We're very encouraged by the outcome of this study because it establishes the foundation for Ampligen as an inter-nasal adjuvant. This shows Ampligen's potential to take us to the next step…

Thank you, ladies and gentlemen. This does conclude today's conference call. You may disconnect your phone lines at this time and have a wonderful day. Thank you for your participation.